Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,301 papers from all fields of science
Search
Sign In
Create Free Account
EMD 273063 antibody, human
Known as:
Hu 14.18/IL - 2 Fusion Protein
, hu14.18-interleukin-2 fusion protein
, EMD 273063
Expand
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Cytotoxic T-Lymphocytes
NCIt Antineoplastic Agent Terminology
Receptor Activation Process
T-Cell Activation
Expand
Broader (2)
Interleukin-2
Monoclonal Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract 4011: Effectivein situimmunization via local radiation therapy (RT) and tumor-specific immunocytokine (IC): Suppression from distant tumor is blocked by RT or Treg-depleting CTLA-4 antibody
Z. Morris
,
Emily I. Guy
,
+10 authors
P. Sondel
2016
Corpus ID: 56783894
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA PURPOSE: Use “off the shelf” reagents to…
Expand
2015
2015
Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model
Z. Morris
,
Emily I. Guy
,
+9 authors
P. Sondel
Journal of Immunotherapy for Cancer
2015
Corpus ID: 41824416
We have identified a cooperative interaction between radiation and intratumoral injection of anti-GD2 immunocytokine (hu14.18-IL2…
Expand
2014
2014
A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma.
M. Albertini
,
E. Ranheim
,
+15 authors
P. Sondel
2014
Corpus ID: 79345466
9044 Background: Phase I testing of the hu14.18-IL2 immunocytokine (IC), a mAb reactive with GD2 disialoganglioside, linked to…
Expand
2013
2013
Abstract 2858: Binding characteristics of the immunocytokine hu14.18-IL2 and induction of human effector functions as anticipated mode of action.
H. Loibner
,
M. Schuster
,
+6 authors
H. Lode
2013
Corpus ID: 70755296
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Immunotherapy of neuroblastoma with anti-GD2…
Expand
2012
2012
Abstract 1538: Enhanced antitumor effects of intratumoral (IT) hu14.18-IL2 immunocytokine (IC) compared to intravenous (IV) hu14.18-IL2 are distinguished by increased activated tumor infiltrating…
Richard K. Yang
,
Nicholas A. Kalogriopoulos
,
+9 authors
P. Sondel
2012
Corpus ID: 71693419
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Introduction: Hu14.18-IL2 (APN301, Apeiron…
Expand
2012
2012
Preclinical and clinical development of intratumorally administered hu14.18-IL2 as treatment for neuroblastoma and melanoma: the importance of tumor infiltrating leukocytes in tumors treated with…
Richard K. Yang
2012
Corpus ID: 79059364
2010
2010
Genotypes of NK cell KIR Receptors , Their Ligands , and Fc γ Receptors in the Response of Neuroblastoma Patients to Hu 14 . 18-IL 2 Immunotherapy : A Children ’ s Oncology Group Report #
D. Delgado
,
J. Hank
,
+14 authors
P. Sondel
2010
Corpus ID: 46735534
Response to immunocytokine (IC) therapy is dependent on natural killer (NK) cells in murine neuroblastoma (NBL) models…
Expand
Review
2008
Review
2008
Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study
S. Shusterman
,
W. London
,
+7 authors
P. Sondel
2008
Corpus ID: 74741270
3002 Background: The hu14.18-IL2 fusion protein consists of IL2 linked to a humanized mAb that recognizes the GD2…
Expand
2008
2008
Phase II trial of hu14.18-IL2 (EMD 273063) for patients with metastatic melanoma
M. Albertini
,
J. Hank
,
+7 authors
P. Sondel
2008
Corpus ID: 78712631
9039 Background: The hu14.18-IL2 immunocytokine consists of a humanized anti-GD2 monoclonal antibody linked to IL2. It has potent…
Expand
2001
2001
Immunozytokine
K. Sturmhoefel
,
A. Harstrick
Der Onkologe
2001
Corpus ID: 264020096
Immuntherapie von Krebs hat eine lange Geschichte. Die bisher erfolgreichsten Ansätze beruhen auf Antikörpern (AK) mit einer…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE